|Description||guselkumab is a selectively blocking agent for interleukin-23 (IL-23), a cytokine involved in plaque psoriasis. guselkumab was approved by FDA as an anti-inflammatory drug for the treatment of moderate to severe plaque psoriasis.|
|Brife Description||selectively blocking agent for interleukin-23 (IL-23), plaque psoriasis|
|Current Developer||Janssen Biotech|
SC144 is an orally active small-molecule gp130 inhibitor (C50 = 0.72 μM).
CP 424174 has been found to be an inhibitor of stimulus-coupled IL-1β post-translational processing.
Ladarixin is Interleukin 8A and Interleukin 8B receptor antagonist. IL-8A and IL-8B inhibition blocks and reverses type 1 diabetes in mice. In Dec 2015, Phase-I...
APY0201, an effective IL-12/23 inhibitor, has been found to have potential useful in treatment of inflammation. IC50: 5.2 nM .
IL5 receptor antagonist
Beta-mangostin, a natural product extracted from the fruits of Garcinia mangostana, can reduced the levels of TNF-α and IL-1β in peritoneal fluid.
Veledimex S enantiomer
Veledimex S enantiomer is the S enantiomer of veledimex which is an orally active small molecule diacylhydrazine and controls the expression of the target gene.
CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation.